BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...

Management expects cash burn to hold steady through 2026 and start declining by the end of next year, driven by increasing Attruby revenues and improved operating leverage. Kumar said, "Our current ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...

Attruby (acoramidis) can cause certain side effects, including diarrhea and pain in the upper abdomen. Serious side effects haven’t been reported with Attruby. If you experience side effects that are ...

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby contains the active ingredient ...

The digital era has reigned for a long time already, but in recent years, many brands and companies have developed modern retro technology, including the resurrection of MP3 players. MP3 players ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 3 minutes If ...

NEW YORK--(BUSINESS WIRE)--Ostro, the leader in agentic AI omnichannel engagement platform for life sciences, is proud to announce its inclusion on the Inc. Best in Business list in the Best AI ...

Through the looking glass: Nearly three decades after its US patent date, the MP3 is no longer the cutting edge of audio compression. Yet support for it remains ubiquitous in media players, browsers, ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.95 EPS, expectations were $-0.88.